Clinical and Economic Burden of Managing Patients with Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions in the United States
Despite utilizing available care with frequent RBCTs, patients with SCD experienced a variety of disease and transfusion-related complications, including frequent VOCs and iron overload, which led to substantial HCRU and costs. These findings highlight the need for novel therapies for this patient group.
Authors
- Nanxin Li (ORCID: https://orcid.org/0009-0006-4412-0997)
- C. Udeze (ORCID: https://orcid.org/0009-0002-7840-6804)
- Michelle Jerry (ORCID: https://orcid.org/0000-0003-1664-8090)
- Biree Andemariam (ORCID: https://orcid.org/0000-0002-2540-6037)
- Kristin Evans (ORCID: https://orcid.org/0000-0003-0987-1745)
- Siddharth Jain (ORCID: https://orcid.org/0009-0001-1579-4275)
Institutions
- Analytical Services (US)
- Vertex Pharmaceuticals (United States) (US)
- UConn Health (US)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/ceor.s511996
- Citations
- 1
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Vertex Pharmaceuticals